10/2021. MV140 results in recurrent UTIs

The results of the phase III clinical trial with MV140 have been presented at the ICS 2021 (International Continence Society) congress for the prevention of recurrent urinary tract infections (UTIs).   

MV140 is a sublingual bacterial vaccine developed by INMUNOTEK with effectiveness for the prevention of recurrent UTIs according to previous uncontrolled studies. The results presented by Dr. Mª Fernanda Lorenzo-Gómez (Complejo Asistencial Universitario de Salamanca, principal investigator of the study), entitled “MV140 Sublingual Vaccine Prevents Recurrent Urinary Tract Infections in Women” confirm the efficacy of this vaccine in a phase III, double-blind, placebo-controlled trial on 240 women, conducted in a multicenter manner between Spain and the United Kingdom.

These results have also been presented in:

  • June 2021. The British Association of Urological Surgeons (BAUS2021 Meeting. 2021)Yang B. Sublingual vaccination with Uromune (MV140) prevents recurrent urinary tract infections in women.
    Preliminary results from a multicentre, Spanish-UK randomized, double-blind, placebo-controlled phase III trial.
  • July 2021.  European Association of Urology (EAU21 Conference. 2021)  Lorenzo-Gómez M, Foley, S, Nickel, JC, Padilla-Fernández, BY, Martínez-Huélamo, M, Yang, B, Saz-Leal, P, Casanovas, M, García-Cenador, MB. Efficacy and safety of the sublingual bacterial vaccine MV140 in women with recurrent urinary tract infections: a European phase III, multicentre, randomized, double-blind, placebo-controlled trial.
  • September 2021. American Urological Association (AUA annual meeting-2021)Nickel JC, Lorenzo-Gómez MF, Foley S, Saz-Leal P. A Novel Sublingual Vaccine Will Dramatically Alter the Clinical Management of Recurrent Urinary Tract Infections in Women.